Jürgen Kuball, MD, PhD, Utrecht University, Utrecht, Netherlands, gives an update on off-the-shelf chimeric antigen receptor T-cells (CAR-Ts). Manufacturing autologous CAR-Ts is a time-consuming process and access to CAR-Ts is limited. Off-the-shelf CAR-Ts represent a promising alternative to autologous CAR-T technology. However, several challenges including limited CAR-T persistence remain and need to be addressed before implementing allogeneic CAR-Ts in the clinic. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.